IP Library Granted Patent US 12685732
Granted Patent B2
US 12685732 · App. 18/296,796 · Granted Jul 21, 2026

Composition for improving, preventing or treating muscular disorders including sulfonamide-based compounds

Inventors: Jongsun Park (Daejeon, KR); Jisoo Park (Chungcheongnam-do, KR); Hyunji Lee (Daejeon, KR)
Assignee: The Industry & Academic Cooperation in Chungnam National University (IAC)
A61K31/505A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685732
App. No.
18/296,796
Filed
Apr 6, 2023
Granted
Jul 21, 2026
Kind
B2
Art Unit
1691
USPC
514/49
Abstract

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

Claims (7)

1 . A method for preventing inhibition of myoblast differentiation comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising one or more of sulfonamide-based compounds of Chemical Formula 1 below or a pharmaceutically acceptable salt thereof to decrease the expression of PHF20 and YY1:

wherein R 1 is hydrogen, C(═N)NH 2 , acetyl, or C 5-6 aryl or heteroaryl, wherein R 1 is optionally substituted with at least one substituent selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, and phenyl, and R 2 is —NH 2 or

2 . The method of claim 1 , wherein the aryl or heteroaryl includes thiazole, diazole, thiadiazole, phenyl, pyridine or pyrimidine, and the aryl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, and phenyl.

3 . The method of claim 1 , wherein the at least one substituent selected from the group consisting of C 1-3 alkyl and C 1-3 alkoxy is methyl or methoxy.

4 . The method of claim 1 , wherein the sulfonaminde-based compound is selected from the group consisting of sulfasalazine, sulfamethazine, sulfathiazole, sulfapyridine, sulfaphenazole, sulfameter, sulfamethizole, sulfaguanidine, sulfacetamide, sulfadoxine, sulfadimethoxine, sulfanilamide, and sulfadiazine.

5 . The method of claim 1 , wherein the composition is a pharmaceutical composition or a food composition.

6 . The method of claim 1 , wherein the subject is a human.